Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 6401 - 6408 of 11533 results
Business Immigration Mostly Untouched by New Travel Ban Standard
June 27, 2017| News
U.S. Supreme Court Holds that the Filing of a Class Action Does Not Toll the Securities Act's Statute of Repose
June 27, 2017| Blog| Viewpoint
Capitol Hill Update: Affordable Care Act Repeal on the Ropes?
June 27, 2017| Blog| Viewpoint
What’s CHIP Got to Do With It?
June 27, 2017| Blog| Viewpoint
USCIS Introduces Redesigned I-485 Application Form
June 27, 2017| Alert| Viewpoint
June Washington Update
June 26, 2017| Blog| Viewpoint
News & Press Releases
Mintz Advises Aspen Aerogels on $98M Follow-on Offering
November 19, 2024
Mintz advised Aspen Aerogels, Inc. (NYSE: ASPN), a technology leader in sustainability and electrification solutions, on a registered follow-on offering of 4,887,500 shares of its common stock, which included 637,500 shares pursuant to the underwriters’ option to purchase additional shares of its common stock. The price to the public in the offering was $20.00 per share and the gross proceeds to Aspen from the offering were approximately $98 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Mintz Recovers Over $400M for Institutional Investor Clients in 2024
November 14, 2024
Mintz's Institutional Investor Class Action Recovery Practice has recovered $400 million for institutional investor clients in 2024 and expects projects for recoveries exceeding $500 million by year end.
Structuring Your Company for Cross-Border Opportunities in Life Sciences
November 14, 2024
An article written by International Life Sciences Chair Cheryl Reicin and Associate Luke Jeagal was published in BIOTECanada's Insights Magazine focusing on how life sciences companies should structure themselves so that they have cross-border opportunities.